Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

HIV Clinic, University of Nebraska Medical Center, Omaha, NE, USA.
BMC Infectious Diseases (Impact Factor: 2.61). 04/2005; 5(1):23. DOI: 10.1186/1471-2334-5-23
Source: PubMed


Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir (ABC) and didanosine (ddI), and would be expected to improve virologic efficacy.
A 48-week, phase IV, multicenter, open-label, proof-of-concept clinical trial was conducted to evaluate second-line, protease inhibitor (PI)-sparing therapy with ABC/efavirenz (EFV)/ddI plus HU or without HU in HIV-infected subjects failing to achieve HIV-1 RNA < or = 400 copies/mL after > or = 16 weeks of treatment with lamivudine/zidovudine or lamivudine/stavudine, plus 1 or 2 PIs. Subjects were assigned to ABC (300 mg twice daily)/ EFV (600 mg once daily)/ ddI (400 mg once daily) plus HU (500 mg twice daily) (n = 30) or this regimen without HU (n = 24).
Baseline mean HIV-1 RNA was 3.86 log10 copies/mL and CD4+ cell count was 345 cells/mm3. A similar percentage of subjects in the non-HU arm (58%) and HU arm (53%) completed the study. Intent-to-treat: missing = failure analysis showed no differences in proportions of subjects in the non-HU and HU arms achieving undetectable plasma HIV-1 RNA levels at week 24 (< 400 copies/mL: 58% [14/24] vs 57% [17/30], P = 0.899; < 50 copies/mL (50% [12/24] vs 47% [14/30], P = 0.780). Median change from baseline in CD4+ cell count in the non-HU and HU arms at week 48 was +114 cells/mm3 and -63 cells/mm3 (P = 0.007), respectively. Both regimens were generally well tolerated, although more subjects in the HU arm withdrew prematurely from the study due to adverse events (23% vs 4%). Four cases of possible ABC-related hypersensitivity were observed.
ABC/EFV/ddI was an effective and well-tolerated second-line regimen for nucleoside/PI-experienced HIV-infected subjects. The addition of HU blunted the CD4+ cell response, did not appear to enhance antiviral activity, and resulted in more treatment-limiting adverse events.

Download full-text


Available from: Jaime Hernandez, Oct 20, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: More than two decades after the recognition of HIV-1, not a single person has been cured. Although dramatic decreases in morbidity and mortality have been obtained with therapy, life-long antiretroviral therapy remains unrealistic for most patients. Replication-competent HIV-1 remains present in cellular and anatomical reservoirs even after years of undetectable viremia, leading to replication rebound each time therapy is interrupted. Advances have been made over the past few years in designing new potentially therapeutic avenues to overcome HIV persistence. Although the first results obtained with non-specific immune stimulation, such as IL-2, have been disappointing in reducing the reservoir, several new drugs have been tested in vitro that could be of outstanding interest. These promising molecules include IL-7, prostratin, and HDAC inhibitors. The first clinical results using this last class of drugs have renewed optimism. Beside this approach, improvements have also been made in designing new tools to kill infected cells (immunotoxins), block HIV expression (RNA silencing), or control it (gene therapy). This review focuses on the latest developments in the biology of HIV persistence, and envisages possible strategies to target HIV reservoirs. Currently available data allow the proposal of a combined and stepwise approach to be tested in several proof-of-concept trials.
    Current opinion in HIV and AIDS 04/2006; 1(2):141-6. DOI:10.1097/01.COH.0000209584.89952.53 · 4.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Combination antiretroviral therapy (ART) has transformed the care of individuals who have HIV infection. Effective ART has resulted in dramatic reductions in mortality, hospitalization rates, and the development of AIDS-defining illnesses. This article discusses the variety of agents that can comprise an effective ART regimen, focusing on the basic principles of ART, the indications for initiating ART in treatment-naive individuals who have established HIV infection, and the challenges associated with the use of antiretroviral medications.
    Dermatologic Clinics 11/2006; 24(4):537-47, vii. DOI:10.1016/j.det.2006.06.012 · 1.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ribavirin (RBV) is used for the treatment of hepatitis C virus (HCV) infection in subjects with HIV-1 infection who may require antiretroviral treatment (ART) with nucleoside reverse transcriptase inhibitors including zidovudine (ZDV). We sought to investigate the potential antagonism between RBV and ZDV by evaluating the impact of RBV on the formation of intracellular ZDV triphosphate (TP) in HIV-infected patients receiving ZDV who were treated for HCV infection. Serial plasma and intracellular ZDV TP pharmacokinetics (PK) were determined in 14 subjects at entry (within 2 weeks prior to RBV administration) and at 8 weeks following initiation of RBV. Intracellular ZDV TP in peripheral blood mononuclear cells (PBMC) was quantified by a validated cartridge/liquid chromatography/tandem mass spectrometry method. PK exposure was estimated from the steady-state area under the concentration vs time curve (AUC(0-12 h)) in plasma and PBMC. Ribavirin did not have a statistically significant impact on ZDV TP AUC(0-12 h), plasma ZDV AUC(0-12 h) or the ratio of ZDV TP AUC(0-12 h) to plasma ZDV AUC(0-12 h), although there was a trend towards an increase post-RBV ratio compared with pre-RBV. There was extensive variability in the ZDV TP AUC(0-12 h). Ribavirin did not inhibit formation of ZDV TP in PBMC in 14 patients receiving ZDV as part of ART and RBV-based HCV therapy for 8 weeks. These results are consistent with those of a previously published limited study in seven subjects. These PK findings should be weighed carefully against emerging clinical reports of significant anaemia associated with combination ZDV and high-dose RBV therapy.
    HIV Medicine 08/2007; 8(5):288-94. DOI:10.1111/j.1468-1293.2007.00472.x · 3.99 Impact Factor
Show more